We’ve harnessed the power of our LiquiXR® technology to develop a comprehensive and expanding portfolio of leading ADHD therapies that enhance patient care and experience for individuals with the disorder.
Our therapies are designed to provide consistent delivery of ADHD medications despite patient-to-patient variability because of the medications’ smooth-release profile. The therapies are available in both oral suspension (liquid) and solid (tablet) forms. View clinical publications supporting our ADHD medicines.
The portfolio currently features five FDA-approved ADHD medications for the treatment of individuals six years of age and older.
NEWLY APPROVED
Extended-release LIQUID
DYANAVEL XR, Quillivant XR and QuilliChew ER have a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DYANAVEL XR, Quillivant XR and QuilliChew ER, can result in overdose and death. Before prescribing DYANAVEL XR, Quillivant XR or QuilliChew ER, assess each patient’s risk for abuse, misuse and addiction. Educate patients and their families about these risks, proper storage of the drug and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse and addiction.
Tell your doctor if you, your child or any family members have ever abused or been dependent on alcohol, prescription medicines or street drugs.
ADHD resources for physicians, caregivers and patients are available.
Our ADHD therapies harness LiquiXR® technology
Our LiquiXR® technology allows for medicines that: 1-2
- have extended-release of medication
- can be tailored with a smooth, consistent release profile
- are available as liquid or tablet and have flexible dosing options
DYANAVEL and LiquiXR® are registered trademarks of Tris Pharma, Inc. Quillivant XR and QuilliChew ER are registered trademarks of NextWave Pharmaceuticals, Inc.
NextWave Pharmaceuticals, Inc. is a wholly owned subsidiary of Tris Pharma, Inc.
1 Pardo A, Kando JC, King TR, Rafla E, Herman BK. Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension. CNS Spectr. 2020;25(6):774-781.
2 Kando JC, King TR, Pardo A. A novel, modified release drug delivery technology containing amphetamine and methylphenidate ion-exchange complexes. Poster presented at American Psychiatric Association Annual Meeting; May 1-3, 2021.